




A



B



C



Supplement Table S1. The Network Meta-analysis Results of Therapy Strategies for Each BCLC stage.

| Items | Comparisons | | | | | | | |
|--|--------------------|--------------------|--------------------|--------------------|---------------------|---------------------|---------------------|--|
| BCLC Stage A. 1-year overall survival | | | | | | | | |
| PAI | 1.02 (0.10, 9.12) | 0.83 (0.09, 8.58) | 0.85 (0.02, 37.45) | 1.63 (0.14, 24.54) | 2.76 (0.04, 283.02) | 2.50 (0.11, 118.04) | 2.84 (0.06, 189.09) | |
| 0.98 (0.11, 10.43) | PEI | 0.83 (0.24, 3.92) | 0.83 (0.03, 22.99) | 1.63 (0.28, 13.99) | 2.79 (0.07, 168.84) | 2.55 (0.18, 74.19) | 2.83 (0.09, 129.12) | |
| 1.20 (0.12, 11.25) | 1.20 (0.25, 4.21) | RFA | 0.99 (0.05, 19.34) | 1.95 (0.55, 7.53) | 3.34 (0.07, 229.48) | 3.08 (0.29, 57.42) | 3.35 (0.13, 104.56) | |
| 1.18 (0.03, 46.55) | 1.20 (0.04, 29.19) | 1.01 (0.05, 18.45) | RFA+125I | 1.99 (0.09, 50.94) | 3.30 (0.03, 515.41) | 3.13 (0.07, 182.90) | 3.32 (0.05, 300.25) | |
| 0.61 (0.04, 7.06) | 0.62 (0.07, 3.58) | 0.51 (0.13, 1.81) | 0.50 (0.02, 11.46) | SR | 1.69 (0.03, 144.20) | 1.57 (0.16, 23.13) | 1.74 (0.09, 40.54) | |
| 0.36 (0.00, 24.13) | 0.36 (0.01, 13.78) | 0.30 (0.00, 14.95) | 0.30 (0.00, 37.89) | 0.59 (0.01, 39.21) | TACE+PEI | 0.96 (0.01, 131.72) | 0.99 (0.00, 194.77) | |
| 0.40 (0.01, 9.10) | 0.39 (0.01, 5.54) | 0.32 (0.02, 3.49) | 0.32 (0.01, 13.74) | 0.64 (0.04, 6.14) | 1.04 (0.01, 130.45) | TACE+RFA | 1.09 (0.02, 48.57) | |
| 0.35 (0.01, 18.17) | 0.35 (0.01, 11.44) | 0.30 (0.01, 7.68) | 0.30 (0.00, 21.99) | 0.57 (0.02, 11.20) | 1.01 (0.01, 210.93) | 0.92 (0.02, 56.89) | TACE+SR | |
| BCLC Stage A. 3-year overall survival | | | | | | | | |
| PAI | 0.94 (0.23, 3.77) | 1.21 (0.29, 5.08) | 1.21 (0.09, 16.23) | 2.92 (0.61, 14.98) | 2.11 (0.21, 22.75) | 1.66 (0.31, 11.28) | 3.13 (0.33, 33.90) | |
| 1.06 (0.27, 4.31) | PEI | 1.30 (0.52, 3.19) | 1.28 (0.11, 14.25) | 3.10 (1.01, 10.29) | 2.23 (0.35, 14.83) | 1.77 (0.48, 8.23) | 3.39 (0.44, 28.23) | |
| 0.82 (0.20, 3.41) | 0.77 (0.31, 1.94) | RFA | 0.98 (0.10, 9.04) | 2.41 (1.19, 5.23) | 1.73 (0.21, 14.32) | 1.38 (0.52, 4.54) | 2.59 (0.41, 17.35) | |
| 0.82 (0.06, 11.52) | 0.78 (0.07, 9.12) | 1.02 (0.11, 9.82) | RFA+125I | 2.42 (0.24, 25.79) | 1.74 (0.09, 39.14) | 1.43 (0.12, 17.97) | 2.69 (0.14, 50.66) | |
| 0.34 (0.07, 1.65) | 0.32 (0.10, 0.99) | 0.42 (0.19, 0.84) | 0.41 (0.04, 4.24) | SR | 0.72 (0.08, 6.62) | 0.57 (0.20, 1.92) | 1.08 (0.19, 6.22) | |
| 0.47 (0.04, 4.88) | 0.45 (0.07, 2.87) | 0.58 (0.07, 4.76) | 0.57 (0.03, 11.69) | 1.38 (0.15, 12.98) | TACE+PEI | 0.79 (0.08, 9.00) | 1.49 (0.09, 24.25) | |
| 0.60 (0.09, 3.24) | 0.57 (0.12, 2.08) | 0.72 (0.22, 1.92) | 0.70 (0.06, 8.22) | 1.76 (0.52, 4.89) | 1.26 (0.11, 11.95) | TACE+RFA | 1.90 (0.23, 14.14) | |
| 0.32 (0.03, 3.06) | 0.29 (0.04, 2.29) | 0.39 (0.06, 2.41) | 0.37 (0.02, 6.96) | 0.93 (0.16, 5.13) | 0.67 (0.04, 10.55) | 0.53 (0.07, 4.41) | TACE+SR | |
| BCLC Stage A. 5-year overall survival | | | | | | | | |
| PEI | 1.08 (0.31, 3.87) | 2.14 (0.34, 14.14) | 2.84 (0.46, 16.92) | 1.19 (0.24, 5.77) | 2.54 (0.26, 21.25) | 4.15 (0.43, 39.29) | | |
| 0.92 (0.26, 3.25) | RFA | 2.00 (0.51, 7.84) | 2.61 (0.71, 9.28) | 1.07 (0.15, 8.71) | 2.32 (0.36, 13.43) | 3.82 (0.56, 24.42) | | |
| 0.47 (0.07, 2.92) | 0.50 (0.13, 1.97) | RFA+125I | 1.31 (0.18, 8.62) | 0.55 (0.04, 6.51) | 1.15 (0.11, 11.18) | 1.90 (0.17, 20.22) | | |
| 0.35 (0.06, 2.17) | 0.38 (0.11, 1.42) | 0.77 (0.12, 5.48) | SR | 0.42 (0.04, 4.71) | 0.88 (0.25, 3.12) | 1.48 (0.36, 5.82) | | |
| 0.84 (0.17, 4.10) | 0.93 (0.11, 6.86) | 1.82 (0.15, 22.27) | 2.39 (0.21, 28.36) | TACE+PEI | 2.15 (0.13, 33.49) | 3.58 (0.22, 58.18) | | |
| 0.39 (0.05, 3.85) | 0.43 (0.07, 2.82) | 0.87 (0.09, 9.16) | 1.14 (0.32, 4.02) | 0.47 (0.03, 7.66) | TACE+RFA | 1.66 (0.25, 11.37) | | |
| 0.24 (0.03, 2.35) | 0.26 (0.04, 1.80) | 0.53 (0.05, 5.92) | 0.67 (0.17, 2.80) | 0.28 (0.02, 4.59) | 0.60 (0.09, 4.02) | TACE+SR | | |
| BCLC Stage B. 1-year overall survival | | | | | | | | |
| SR | 0.32 (0.02, 6.15) | 0.92 (0.03, 49.27) | | | | | | |
| 3.15 (0.16, 65.41) | TACE | 2.97 (0.40, 40.00) | | | | | | |
| 1.09 (0.02, 35.81) | 0.34 (0.03, 2.53) | TACE+Sorafenib | | | | | | |
| BCLC Stage B. 3-year overall survival | | | | | | | | |
| SR | 0.18 (0.02, 1.53) | | | | | | | |
| 5.55 (0.65, 49.58) | TACE | | | | | | | |
| BCLC Stage C. 1-year overall survival (Sorafenib vs. SC vs. Sorafenib+CR) | | | | | | | | |
| SC | 1.81 (0.47, 6.84) | 5.73 (0.69, 45.35) | | | | | | |
| 0.55 (0.15, 2.15) | Sorafenib | 3.11 (0.67, 15.36) | | | | | | |
| 0.17 (0.02, 1.45) | 0.32 (0.07, 1.49) | Sorafenib+CR | | | | | | |
| BCLC Stage C. 1-year overall survival (SR+TACE vs. SR vs. SR+TACE+PVC) | | | | | | | | |
| SR | 1.86 (0.72, 5.05) | 3.12 (0.84, 12.32) | | | | | | |
| 0.54 (0.20, 1.39) | SR+TACE | 1.68 (0.43, 6.70) | | | | | | |
| 0.32 (0.08, 1.19) | 0.59 (0.15, 2.34) | SR+TACE+PVC | | | | | | |
| BCLC Stage C. 1-year overall survival (TACE+RFA vs. TACE vs. TACE+Rg3) | | | | | | | | |
| TACE | 4.06 (0.58, 29.00) | 2.19 (0.40, 12.60) | | | | | | |

| | | |
|-------------------|--------------------|-------------------|
| 0.25 (0.03, 1.72) | TACE+RFA | 0.55 (0.04, 6.95) |
| 0.46 (0.08, 2.50) | 1.82 (0.14, 24.57) | TACE+GRg3 |

Supplement Table S2. Results of Node-splitting Models for the Test of Difference Between Direct and Indirect Effect in the Analysis of Primary Outcomes.

| Items | Comparison | Direct Effect | Indirect Effect | Overall | <i>P</i> value |
|--|--------------------------|---------------------|---------------------|---------------------|----------------|
| BCLC Stage A. 1-year overall survival | | | | | |
| | RFA, SR | 0.49 (-0.84, 1.80) | 17.61 (1.44, 61.34) | 0.68 (-0.59, 2.02) | 0.16 |
| | RFA, TACE+RFA | 22.49 (1.76, 56.91) | 0.19 (-2.99, 3.31) | 1.13 (-1.25, 4.05) | 0.16 |
| | SR, TACE+RFA | -0.34 (-3.26, 2.41) | 19.06 (1.08, 90.92) | 0.45 (-1.81, 3.14) | 0.11 |
| BCLC Stage A. 3-year overall survival | | | | | |
| | RFA, SR | 0.83 (-0.00, 1.71) | 1.28 (-0.77, 3.59) | 0.88 (0.18, 1.65) | 0.65 |
| | RFA, TACE+RFA | 0.54 (-0.84, 2.11) | 0.06 (-1.82, 2.02) | 0.32 (-0.65, 1.51) | 0.64 |
| | SR, TACE+RFA | -0.76 (-2.42, 0.98) | -0.31 (-1.92, 1.54) | -0.56 (-1.59, 0.65) | 0.65 |